|
We asked 40 leaders, What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients |
19% |
Restricts innovation and the development of new drugs |
51% |
Has no impact on drug development |
1% |
Don’t Know |
19% |
 |
|
|
|
|
|
|
|
10 June, 2014
|
|
Surviving the Emerging Market Price Wars
How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment...Read more |
Immunotherapies: The New Hope for Cancer Treatment
The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey ... Read more
|
The Urge to Merge: Deal-Making Lessons from History
The rationale for pharmaceutical industry merger activity over the past two decades has been the perceived need for increased economies of scale, improved R&D productivity, access to new technologies or geographies, and increased exposure to patent loss and generic competition. However, developing and rapidly ramping up new drugs to replace the lost revenue—particularly in the US—has proven difficult, writes Cliff Kalb ... Read more
|
Sanofi Responds to UK’s Value-Based Assessment Plans
The UK’s National Institute for Health and Care Excellence set out their proposals for value-based assessment (VBA) in March 2014. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 approaches. But Sanofi have gone further than some in sharing their thinking early ... Read more
|
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ... Read more
|
|
|
|
|